Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Not yet recruiting · NCT07793253 · Registry updated 2026-08-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | Biliary Tract Neoplasms, Cirrhosis, Familial, with Pulmonary Hypertension, Digestive System Diseases, Digestive System Neoplasms, Extrahepatic Cholangiocarcinoma, Liver Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, biliary tract cancer, biliary tract disorder, carcinoma, carcinoma of the ampulla of vater, cholangiocarcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gallbladder carcinoma, gallbladder disorder, gallbladder neoplasm, liver disorder, neoplasm | Not yet recruiting | Phase 2 | 2026-08-28 | NCT07793253 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cholangiocarcinoma Foundation | 1 |
| Revolution Medicines, Inc. | 18 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sidney Kimmel Comprehensive Cancer Center | Baltimore | United States | 9 |